"We believe that MultiStem has the potential to improve standard of care for patients that have suffered a stroke while also extending the treatment window, providing a potential treatment option for many more patients," said Athersys interim CEO William Lehmann, Jr. "We look forward to the topline results which Healios is targeting for release later this year."
Shares of Athersys were up nearly 6% in midday trading.
Price: 1.63, Change: +0.10, Percent Change: +6.21
|Insider Sell: Neurocrine Biosciences|
|Sonoco Completes Acquisition of Ball Metalpack for $...|
|Insider Sell: Intuitive Surgical|
|Market Chatter: Tencent Reportedly Plans to Take Dou...|
|SMBC Nikko Securities Starts DLocal at Neutral With ...|